Impact Of Rising Chronic Eye Conditions On Vision Loss And Treatment Demand: Major Factor in the Transformation of the Glaucoma Market in 2025

How Will the Glaucoma Market Grow, and What Is the Projected Market Size?
The dimension of the glaucoma market has seen significant expansion in past years. The market, set to escalate from $7.76 billion in 2024 to $8.22 billion in 2025, demonstrates a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this growth during the historic period include enhanced eye health consciousness, amplified healthcare expenditure, the rising use of telemedicine in eye care, growth in healthcare infrastructure, and government initiatives to improve healthcare.

In the upcoming years, the glaucoma market size is forecasted to experience robust expansion, escalating to $10.20 billion in 2029 with a compound annual growth rate (CAGR) of 5.5%. The growth during the prediction period is credited to factors like an increasing elderly population, the escalating occurrence of glaucoma, surging demand for less invasive surgeries, an increase in diabetes cases, and a rise in hypertension. Key trends for the forecast period encompass progress in diagnostic technology, introduction of novel drug therapies, technological breakthroughs in surgical equipment, the presence of combination treatments, and the acceptance of robot-assisted surgeries.

What Key Elements Are Boosting Growth in the Glaucoma Market?
The growth of the glaucoma market is anticipated to be propelled by the increasing incidence of chronic eye diseases. Chronic eye diseases are enduring disorders that affect the eyes, often causing sustained visual impairment or discomfort and demand constant management or treatment. The rising occurrence of chronic eye diseases can be attributed to aging populations, an increase in screen time, lifestyle factors, and an increased frequency of conditions such as diabetes and hypertension. Glaucoma treatment is necessary to reduce intraocular pressure, avert further damage to the optic nerve, and save vision, as unchecked glaucoma can lead to irreversible blindness. For example, as reported by the National Health Service (NHS), a publicly funded healthcare platform in the UK, in December 2024, over 2 million individuals in the UK are experiencing sight loss in 2024. Moreover, the tally of people living with sight loss is foreseen to increase by 27%, hitting approximately 2.8 million by 2035. Hence, the escalating incidence of chronic eye conditions is fueling the glaucoma market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

Who Are the Major Industry Players Fueling Glaucoma Market Expansion?
Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

What Are the Emerging Trends in the Glaucoma Industry?
Key players in the glaucoma market are directing their efforts towards the creation of pioneering treatments like Rho-kinase (ROCK) inhibitors. These drugs offer two-pronged benefits: they enhance the flow of aqueous humor and relax trabecular meshwork cells, both fundamental processes in mitigating glaucoma. ROCK inhibitors interfere with Rho-kinase enzymes that regulate cell contraction, thus reducing intraocular pressure, a key element in managing glaucoma. Case in point, in July 2023, Santen Pharmaceutical Co. Ltd., a Japanese firm specializing in eye health products, introduced Roclanda in the UK. This medication combines latanoprost and netarsudil, a new ROCK inhibitor, into a fixed-dose treatment that tackles intraocular pressure (IOP) by dealing with issues in the trabecular meshwork. It's intended for adults with primary open-angle glaucoma or ocular hypertension, whose IOP hasn't been sufficiently reduced by a single-drug treatment of either prostaglandin or netarsudil. Roclanda's emergence in Europe represents the inaugural new category of glaucoma drugs in a quarter-century, marking a significant advancement in treatment solutions. Owing to the amalgamation of netarsudil and latanoprost, Roclanda enhances the flow along both the conventional (trabecular) and unconventional (uveoscleral) routes, thus offering a comprehensive strategy in the management of elevated IOP.

How Is the Segmentation of the Glaucoma Market Defined?
The glaucoma market covered in this report is segmented -

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types
2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy
3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes
4) By Administration: Oral, Injections, Intravitreal, Other Administrations
5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

What Is the Leading Region in the Glaucoma Market?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Glaucoma Global Market Report?

- Market Size Analysis: Analyze the glaucoma Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the glaucoma Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall glaucoma market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the glaucoma market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.